The recently announced £650 million life sciences package will support the delivery of plans for accelerating the development, adoption and spread of innovation to bring new products to patients faster, in line with the Life Sciences Vision (LSV). Through the LSV, we are also advancing plans for a new regulatory pathway, which will facilitate the development and uptake of beneficial innovative technologies, and are progressing work to improve the capability to generate Real World Evidence, which will support the National Health Service in selecting products that provide positive patient outcomes.

The Government's new Medical Technology Strategy, published in February 2023, builds on the LSV to set out how the health and social care system can reliably access safe, effective and innovative medical technologies that support the continued delivery of high-quality care, outstanding patient safety and excellent patient outcomes in a way that makes the best use of taxpayer money.

Through the Medical Technology Strategy, we are working closely with NHS Supply Chain and NHS England to implement a consistent methodology for value-based procurement to be adopted at a national and local level and ultimately to provide positive patient outcomes.

The Government's new Medical Technology Strategy, published in February 2023, commits to ensuring the right medtech products are available at the right price and in the right place. To ensure the best value for public money, the strategy recognises that the value of medtech products should not be considered in isolation, but across the whole patient pathway, and that the lowest price does not always mean the best value. The Department’s Medtech Directorate is working closely with NHS Supply Chain and NHS England to build on the work already undertaken on the application and adoption of Value Based Procurement (VBP) to develop a consistent methodology to be adopted at both a national and local level.

The Government is committed to the development of alternatives to using animals in scientific procedures and through UK Research and Innovation (UKRI) provides core funding for the National Centre for 3Rs (replacement, reduction and refinement) (NC3Rs), which works nationally and internationally to drive the uptake of non-animal technologies. The UK has a world leading reputation for the delivery of the 3Rs principles and the NC3Rs is widely recognised as being world leading, supporting research and innovation that provides researchers in academia and industry with technologies that are more predictive, cost-effective and humane than current animal models.

The Government is committed to the development of alternatives to using animals in scientific procedures and continues to actively support and fund the development and dissemination of the 3Rs (replacement, reduction and refinement) for the use of animals in scientific procedures. This is achieved through UK Research and Innovation’s funding of the National Centre for the 3Rs, which works nationally and internationally to drive the uptake of non-animal technologies, and through research into the development of alternatives by Innovate UK, the Medical Research Council, and the Biotechnology and Biological Sciences Research Council.

The Government is committed to the development of alternatives to using animals in scientific procedures and continues to actively support and fund the development and dissemination of the 3Rs (replacement, reduction and refinement) for the use of animals in scientific procedures. This is achieved through UK Research and Innovation’s funding of the National Centre for the 3Rs, which works nationally and internationally to drive the uptake of non-animal technologies, and through research into the development of alternatives by Innovate UK, the Medical Research Council, and the Biotechnology and Biological Sciences Research Council.

The Elective Recovery Taskforce aims to reduce waiting lists and ensure patients can access elective services as soon as possible. The Taskforce will consider the deployment of technical interventions, such as virtual appointments, to reduce waiting times for elective care. While the Taskforce does not have a clinical remit, it may hear evidence of specific technological interventions.

The hon. Gentleman raises an important point. We had that extra £1.8 billion in the most recent Budget because this is the exactly the sort of area we will look at. I assure him that I have regular meetings with industry and with the forces to talk about those very issues.

The supplier base for different products is constantly changing and therefore the Department and NHS Supply Chain continuously monitor developments in the medical technology sector to identify any material implications for the marketplace and continuity of supply.